



## Ionis to present at upcoming investor conferences

February 19, 2026

CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 19, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

- Oppenheimer 36<sup>th</sup> Annual Healthcare Life Sciences Virtual Conference on Thursday, February 26, 2026
- TD Cowen 46<sup>th</sup> Annual Health Care Conference on Monday, March 2, 2026
- Leerink Global Healthcare Conference on Monday, March 9, 2026
- Barclays 28<sup>th</sup> Annual Global Healthcare Conference on Wednesday, March 11, 2026
- Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at <https://ir.ionis.com/events-and-presentations/upcoming-events>. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

### About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit [ionis.com](https://ionis.com) and follow us on [X](#) (Twitter), [LinkedIn](#) and [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260219233764/en/): <https://www.businesswire.com/news/home/20260219233764/en/>

### Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. – [ir@ionis.com](mailto:ir@ionis.com) – 760-603-2331

### Ionis Pharmaceuticals Media Contact:

Hayley Soffer – [media@ionis.com](mailto:media@ionis.com) – 760-603-4679

Source: Ionis Pharmaceuticals, Inc.